JP2025502023A - デューピルフェニドンにより特発性肺線維症を治療する方法 - Google Patents

デューピルフェニドンにより特発性肺線維症を治療する方法 Download PDF

Info

Publication number
JP2025502023A
JP2025502023A JP2024540710A JP2024540710A JP2025502023A JP 2025502023 A JP2025502023 A JP 2025502023A JP 2024540710 A JP2024540710 A JP 2024540710A JP 2024540710 A JP2024540710 A JP 2024540710A JP 2025502023 A JP2025502023 A JP 2025502023A
Authority
JP
Japan
Prior art keywords
treatment
lyt
subject
pirfenidone
tid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024540710A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025502023A5 (enExample
Inventor
チェン，マイケル・シィ
エレンコ，エリック
パデン，ヘザー・エイ
コース，クリストファー・シィ
フォード，ポール・アンドリュー
クロップ，ジュリー・エス
グラハム，カミラ・エス
ミチオーニ，リザ・シィ
ハッチ，サイモン・ジョン
ガーグ，バルン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Puretech LYT 100 Inc
Original Assignee
Puretech LYT 100 Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Puretech LYT 100 Inc filed Critical Puretech LYT 100 Inc
Publication of JP2025502023A publication Critical patent/JP2025502023A/ja
Publication of JP2025502023A5 publication Critical patent/JP2025502023A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2024540710A 2022-01-05 2023-01-05 デューピルフェニドンにより特発性肺線維症を治療する方法 Pending JP2025502023A (ja)

Applications Claiming Priority (31)

Application Number Priority Date Filing Date Title
US202263296818P 2022-01-05 2022-01-05
US202263296826P 2022-01-05 2022-01-05
US202263296843P 2022-01-05 2022-01-05
US63/296,818 2022-01-05
US63/296,826 2022-01-05
US63/296,843 2022-01-05
US202263326132P 2022-03-31 2022-03-31
US202263326129P 2022-03-31 2022-03-31
US63/326,129 2022-03-31
US63/326,132 2022-03-31
US202263341279P 2022-05-12 2022-05-12
US202263341269P 2022-05-12 2022-05-12
US202263341281P 2022-05-12 2022-05-12
US63/341,269 2022-05-12
US63/341,279 2022-05-12
US63/341,281 2022-05-12
US202263341828P 2022-05-13 2022-05-13
US63/341,828 2022-05-13
US202263352107P 2022-06-14 2022-06-14
US63/352,107 2022-06-14
US202263356653P 2022-06-29 2022-06-29
US63/356,653 2022-06-29
US202263374362P 2022-09-01 2022-09-01
US63/374,362 2022-09-01
US202263403481P 2022-09-02 2022-09-02
US63/403,481 2022-09-02
US202263431530P 2022-12-09 2022-12-09
US63/431,530 2022-12-09
US202263432208P 2022-12-13 2022-12-13
US63/432,208 2022-12-13
PCT/US2023/060185 WO2023133476A1 (en) 2022-01-05 2023-01-05 Methods of treating idiopathic pulmonary fibrosis with deupirfenidone

Publications (2)

Publication Number Publication Date
JP2025502023A true JP2025502023A (ja) 2025-01-24
JP2025502023A5 JP2025502023A5 (enExample) 2026-08-13

Family

ID=87074293

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024540710A Pending JP2025502023A (ja) 2022-01-05 2023-01-05 デューピルフェニドンにより特発性肺線維症を治療する方法

Country Status (9)

Country Link
US (1) US20240358690A1 (enExample)
EP (1) EP4460305A4 (enExample)
JP (1) JP2025502023A (enExample)
KR (1) KR20240131352A (enExample)
AU (1) AU2023205787A1 (enExample)
CA (1) CA3239301A1 (enExample)
IL (1) IL314022A (enExample)
MX (1) MX2024008476A (enExample)
WO (1) WO2023133476A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023192646A1 (en) * 2022-03-31 2023-10-05 Puretech Lyt 100, Inc. Methods of treating fibrotic- and collagen-mediated diseases and disorders with deupirfenidone
WO2026133158A1 (en) * 2024-12-16 2026-06-25 Puretech Lyt 100, Inc. Deupirfenidone for use for treating interstitial lung diseases and other fibrotic-mediated pulmonary diseases
WO2026133157A1 (en) * 2024-12-16 2026-06-25 Puretech Lyt 100, Inc. Deupirfenidone for use for treating idiopathic pulmonary fibrosis

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080287508A1 (en) * 2007-05-18 2008-11-20 Intermune, Inc. Altering pharmacokinetics of pirfenidone therapy
AU2008265595B2 (en) * 2007-06-20 2014-12-04 PureTech LYT 100 Inc. Substituted N-Aryl pyridinones as fibrotic inhibitors
US20090131485A1 (en) * 2007-09-10 2009-05-21 Concert Pharmaceuticals, Inc. Deuterated pirfenidone
IL319182A (en) * 2018-09-14 2025-04-01 Puretech Lyt 100 Inc Deuterium-enriched pirfenidone and methods of using it
US20250114341A1 (en) * 2018-09-14 2025-04-10 Puretech Lyt 100, Inc. Methods of treating idiopathic pulmonary fibrosis with deupirfenidone
US20230129866A1 (en) * 2020-03-13 2023-04-27 Puretech Lyt 100, Inc. Methods of treating respiratory disease with deupirfenidone

Also Published As

Publication number Publication date
US20240358690A1 (en) 2024-10-31
AU2023205787A1 (en) 2024-06-13
IL314022A (en) 2024-08-01
WO2023133476A1 (en) 2023-07-13
EP4460305A1 (en) 2024-11-13
EP4460305A4 (en) 2025-12-31
CA3239301A1 (en) 2023-07-13
KR20240131352A (ko) 2024-08-30
MX2024008476A (es) 2024-07-12

Similar Documents

Publication Publication Date Title
Humbert et al. Masitinib, ac‐kit/PDGF receptor tyrosine kinase inhibitor, improves disease control in severe corticosteroid‐dependent asthmatics
Barnes et al. A randomized, double‐blind, placebo‐controlled study of the CRTH2 antagonist OC000459 in moderate persistent asthma
Minoguchi et al. Reduction of eosinophilic inflammation in the airways of patients with asthma using montelukast
US20240358690A1 (en) Methods of treating idiopathic pulmonary fibrosis with deupirfenidone
CN108430475B (zh) 用于治疗慢性咳嗽的奥维匹坦
US9907795B2 (en) Method of treatment of chronic cough administering orvepitant in combination with other therapeutic agents
US20230255946A1 (en) Methods of treating diseases and disorders with deupirfenidone
Medarametla et al. PK10453, a nonselective platelet-derived growth factor receptor inhibitor, prevents the progression of pulmonary arterial hypertension
US12622899B2 (en) Methods of treating idiopathic pulmonary fibrosis with deupirfenidone
TW202342050A (zh) 用於治療進行性纖維化間質性肺病之新穎治療組合
Boettcher et al. Vericiguat in combination with short‐acting nitroglycerin in patients with chronic coronary syndromes: the randomized, phase Ib, VENICE study
EP4244252A1 (en) Treatment of chronic obstructive pulmonary disease with an anti-interleukin-33 antibody
Ortega et al. A phase 2 study to evaluate the safety, efficacy and pharmacokinetics of DP2 antagonist GB001 and to explore biomarkers of airway inflammation in mild‐to‐moderate asthma
Son et al. Pharmacokinetic interaction between rosuvastatin, telmisartan, and amlodipine in healthy male Korean subjects: a randomized, open-label, multiple-dose, 2-period crossover study
KR20210102892A (ko) 과민성 방광 증상의 치료를 위한 비베그론
KR20250150635A (ko) 인자 b 억제제의 사용 방법
Tanaka et al. Randomized, double-blind, placebo-controlled, phase I study of the safety and pharmacokinetics of namilumab in healthy Japanese and Caucasian men
HK40114519A (en) Methods of treating idiopathic pulmonary fibrosis with deupirfenidone
US20250114340A1 (en) Methods of treating interstitial lung diseases and other fibrotic-mediated pulmonary diseases and disorders with deupirfenidone
CN118510510A (zh) 用氘吡非尼酮治疗特发性肺纤维化的方法
Derks et al. Lack of effect of dalcetrapib on QT interval in healthy subjects following multiple dosing
TW202535397A (zh) 給藥方案
US20250025450A1 (en) Methods of treating interstitial lung diseases and other fibrotic-mediated pulmonary diseases and disorders with deupirfenidone
Cai et al. Effects of Rifampicin On Pyrotinib Maleate Pharmacokinetics In Healthy Subjects
HK40100834A (en) Treatment of chronic obstructive pulmonary disease with an anti-interleukin-33 antibody

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251223

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251223

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260803